

IN THE SPECIFICATION:

Please delete the term "novel" from the first line of page 1 and from the Abstract of the Disclosure.

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-13. Canceled

14. (Currently amended) A pharmaceutical composition comprising:

~~Use of at least one medicament selected from the group consisting of Hypericum perforatum Hypericum perforatum (St. John's wort) , and/or Ginkgo biloba (gingko) , and/or Crocus Sativus Crocus Sativus (saffron) and/or Panax ginseng Panax ginseng(ginseng) and pharmaceutical acceptable salts thereof; and~~  
a pharmaceutically acceptable carrier for the production of a medicament for the treatment of schizophrenia.

15. (Previously presented) The pharmaceutical composition according to claim 14 wherein said at least one medicament ~~Use is in a form of , wherein the a plant, plant parts, a dried plant or plant parts, an extract extracts, an extract fraction fractions, pure substances and their derivatives or and the salts of thereof the plant are used.~~

16. (Previously presented) The pharmaceutical composition ~~Use according to~~

claim ~~15~~ 14, wherein the extract used is an alcohol ~~alcoholic, or alcohol-aqueous~~  
~~alcoholic-aqueous~~ extract containing with primary, secondary or and tertiary alcohols  
having 1 to 5 carbons of the series C1 to C5, preferably methanol and ethanol, wherein  
the alcohol/water content of in the composition of ~~alcohol/water of~~ is between 100/0 to  
30/70 by volume, preferably 80/20 to 50/50 by volume.

17. Cancelled.

18. (Currently Amended) The pharmaceutical composition ~~Use~~ according to  
claim ~~15~~ 14, wherein the St. John's wort ~~wart~~ extract comprises the following ~~used has~~  
~~the following amounts of~~ components in weight percent : 0.01 - 2% herpericins, 0.01 -  
30% hyperforins, 2-35% flavonoids, preferably 0.10 to 0.40% hypericins and 1 - 6%  
hyperforins.

19. (Currently Amended) The pharmaceutical composition ~~Use~~ according to claim  
~~15~~ 14, wherein the ginkgo extract comprises the ~~has the~~ following amounts and  
components in weight percent: 20 - 30% by weight percent flavone glycosides, together  
with 2 - 8% of ginkgolides, particularly preferred 23 to 27% flavone glycosides and 5 to 7  
% ~~by weight~~ ginkgolides.

20. (Currently amended) The pharmaceutical composition ~~Use~~ according to claim  
~~15~~ 14, wherein the saffron extract comprises the following components in weight  
percent:  $\alpha$ -,  $\beta$ -pinene, 1, 8 cineol, crocin, picrocrocin as well as optionally the

degradation product thereof safranal, particularly preferred in the following concentrations by weight: 5 - 10% pinene and cineol, 4 - 10% picrocrocin and/or 2-6% safranal.

21. (Currently amended) The pharmaceutical composition ~~Use~~ according to claim 15 ~~14~~, wherein the ginseng root extract comprises the components by weight, inter alia, triterpene saponines (ginsenosides/ginsenoids), sesquiterpenes and polyacetylenes, particularly preferred in the following concentrations: 3 - 9% ginsenoids.

22. (Currently amended) The pharmaceutical composition ~~Use~~ according to claim 14, wherein said pharmaceutical composition is use occurs in the form of a liquid, a semi-solid and a solid forms of administration, such as a solution in particular solutions, a suspension suspensions, a tablet tablets, a film-coated tablet tablets, a dragee dragees, a capsule capsules, an effervescent tablet tablets, an effervescent effervescent granulate, a chewable tablet tablets or and a suppository suppositories.

23. (Currently amended) The pharmaceutical composition ~~Use~~ according to claim 15 ~~14~~, wherein said pharmaceutical composition contains the case of St. John's wort extract , the daily dose of the extracts is 300 to 2700 mg in up to 3 separate doses per day, preferably 750 - 1500 mg of St. John's wort extract.

24. (Currently amended) The pharmaceutical composition ~~Use~~ according to claim 15 ~~14~~, wherein said pharmaceutical composition contains 50 mg - 1000 mg of at least

~~one extract selected from the group consisting of in the case of ginkgo biloba, Crocic sativus and/or Panax ginseng, the daily dose of the extracts is 50 mg - 1000 mg of extract.~~

25. (Currently amended) A pharmaceutical composition in the form of a suspension, a dragee, an effervescent tablet, an effervescent granulate, a chewable tablet or a suppository ~~Combination preparation~~ containing St. John's wort ~~wart~~, ginkgo biloba, saffron and/or Panax ginseng in addition to, as further components, a psychotherapeutic drug ~~against schizophrenia~~ for the simultaneous, separate or graduated ~~use in the~~ treatment of schizophrenia.

Claims 26-28. (Cancelled).

29. (Currently amended) The pharmaceutical composition ~~Use~~ according to claim 15, wherein the St. John's wort ~~wart~~ extract comprises the following ~~used has the following amounts of components~~ by weight percent: 0.01 - 2% hypericins, 0.01 - 30% hyperforins, 2-35% flavonoids, preferably 0.10 to 0.40% hypericins and 1 - 6% hyperforins.

30. (Currently Amended) Use according to claim 16, wherein the St. John's wort ~~wart~~ extract comprises the following ~~used has the following amounts of components~~ by weight percent: 0.01 - 2% hypericins, 0.01 - 30% hyperforins, 2-35% flavonoids, preferably 0.10 to 0.40% hypericins and 1 - 6% hyperforins.

Claims 31-33. (Cancelled).

34. (New) A method for treating schizophrenia, comprising administering a therapeutically effective amount of the pharmaceutical composition of Claim 14.

35. (New) The method for treating schizophrenia of Claim 34 wherein the pharmaceutical composition is administered in combination with at least one drug for treating schizophrenia.

36. (New) The method for treating schizophrenia of Claim 35 wherein the method for treating schizophrenia of Claim 14 wherein the pharmaceutical composition is administered in combination with at least one psychotherapeutic drug for treating neuroleptics.

37. (New) The method for treating schizophrenia of Claim 36 wherein the drug for treating neuroleptics is selected from the group consisting of haloperidol, benperidol, chloroprotixene, flupentixol, fluphenazine, perazine, perphenazine, thioridazine, atypical neuroleptics, clozapine, olanzapine, seroquel, sertindole, and combinations thereof.

38. (New) A method for treating schizophrenia wherein a therapeutically effective amount of the pharmaceutical composition of Claim 23 is administered up to 3 times per day.

39. (New) A method for treating schizophrenia comprising administering the

pharmaceutical composition of Claim 24 wherein the daily dose of the extracts is 50 mg - 1000 mg.

40. (New) A pharmaceutical composition comprising:

at least one medicament selected from the group consisting of *Hypericum perforatum* (St. John's wort) , *Gingko biloba* (gingko) , *Crocus Sativus* (saffron) *Panax ginseng*(ginseng) and pharmaceutical acceptable salts thereof wherein said pharmaceutical composition contains 50 mg -1000 mg of said at least one medicament; and

a pharmaceutically acceptable carrier.

41. (New) The pharmaceutical composition according to Claim 16 wherein the primary alcohol is methanol, ethanol or a combination thereof.